Literature DB >> 10889550

Association and linkage of DRD4 and DRD5 with attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children.

E Tahir1, Y Yazgan, B Cirakoglu, F Ozbay, I Waldman, P J Asherson.   

Abstract

The search for genetic factors predisposing to Attention Deficit Hyperactivity Disorder (ADHD) has focused on genes that regulate dopaminergic pathways such as dopamine receptors and enzymes that regulate levels of dopamine in the synapse. There have been several reports of association between ADHD and polymorphic variants within or near DRD4, DRD5, DAT1, DBH and COMT. In this study we set out to investigate specific alleles of DRD4 and DRD5, previously reported to be associated with ADHD, in a sample of Turkish children with DSM-IV ADHD children, as well as their relation to methylphenidate response and dimensional measures of symptom domains. One hundred and four independent trios and seven dyads were analysed using the transmission disequilibrium test (TDT). We found increased transmission of the DRD4 7-repeat allele (DRD4*7) (TDT chi2 = 2.79, P = 0.047). Given that we were testing specific a priori hypotheses regarding the associated alleles, we have used one-tailed P-values throughout. There was evidence of an interaction with methlyphenidate (MPH) response and analysis of the sample excluding non-responders revealed more significant evidence for the association (TDT chi2 = 4.48, P = 0.017). We also detected a trend for linkage and association in the DRD5 polymorphism (TDT chi2 = 2. 38, P = 0.06). Similar findings were obtained in relation to MPH response as analysis of MPH responders alone gave rise to a more significant association than that of the group as a whole (TDT chi2 = 4.9, P = 0.013). t-Test and logistic regression TDT analyses of DRD4*7 transmission with respect to dimensional rating scales of hyperactivity and impulsivity showed an inverse relation suggesting that in this sample DRD4*7 is associated with a lower level of ADHD symptomatology. While this may be due to stratification along a dimension of severity such that severe cases belong to a more extreme group with other specific genetic and environmental causes, similar to the model for low cognitive ability, it is more likely the result of a chance selection bias in this sample.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10889550     DOI: 10.1038/sj.mp.4000744

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  31 in total

1.  Dopamine D4 receptors modulate brain metabolic activity in the prefrontal cortex and cerebellum at rest and in response to methylphenidate.

Authors:  Michael Michaelides; Javier Pascau; Juan-Domingo Gispert; Foteini Delis; David K Grandy; Gene-Jack Wang; Manuel Desco; Marcelo Rubinstein; Nora D Volkow; Panayotis K Thanos
Journal:  Eur J Neurosci       Date:  2010-07-16       Impact factor: 3.386

2.  Toward a new understanding of attention-deficit hyperactivity disorder: advances in research and treatment.

Authors:  Thomas J Spencer
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

3.  A genomewide scan for attention-deficit/hyperactivity disorder in an extended sample: suggestive linkage on 17p11.

Authors:  Matthew N Ogdie; I Laurence Macphie; Sonia L Minassian; May Yang; Simon E Fisher; Clyde Francks; Rita M Cantor; James T McCracken; James J McGough; Stanley F Nelson; Anthony P Monaco; Susan L Smalley
Journal:  Am J Hum Genet       Date:  2003-04-08       Impact factor: 11.025

4.  The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex.

Authors:  Amy F T Arnsten
Journal:  J Pediatr       Date:  2009-05-01       Impact factor: 4.406

Review 5.  Role of dopamine receptors in ADHD: a systematic meta-analysis.

Authors:  Jing Wu; Haifan Xiao; Hongjuan Sun; Li Zou; Ling-Qiang Zhu
Journal:  Mol Neurobiol       Date:  2012-05-19       Impact factor: 5.590

6.  Attention deficit/hyperactivity disorder: pharmacotherapy.

Authors:  Josephine Elia
Journal:  Psychiatry (Edgmont)       Date:  2005-01

Review 7.  Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.

Authors:  Tanya E Froehlich; James J McGough; Mark A Stein
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

8.  Attention-Deficit Hyperactivity Disorder in the post-genomic era.

Authors:  Philip Asherson
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

9.  Attention deficit hyperactivity disorder: fine mapping supports linkage to 5p13, 6q12, 16p13, and 17p11.

Authors:  Matthew N Ogdie; Simon E Fisher; May Yang; Janeen Ishii; Clyde Francks; Sandra K Loo; Rita M Cantor; James T McCracken; James J McGough; Susan L Smalley; Stanley F Nelson
Journal:  Am J Hum Genet       Date:  2004-08-03       Impact factor: 11.025

10.  Joint analysis of the DRD5 marker concludes association with attention-deficit/hyperactivity disorder confined to the predominantly inattentive and combined subtypes.

Authors:  Naomi Lowe; Aiveen Kirley; Ziarih Hawi; Pak Sham; Harvey Wickham; Christopher J Kratochvil; Shelley D Smith; Saretta Y Lee; Florence Levy; Lindsey Kent; Fiona Middle; Luis A Rohde; Tatiana Roman; Eda Tahir; Yanke Yazgan; Philip Asherson; Jonathan Mill; Anita Thapar; Antony Payton; Richard D Todd; Timothy Stephens; Richard P Ebstein; Iris Manor; Cathy L Barr; Karen G Wigg; Richard J Sinke; Jan K Buitelaar; Susan L Smalley; Stan F Nelson; Joseph Biederman; Stephen V Faraone; Michael Gill
Journal:  Am J Hum Genet       Date:  2004-01-19       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.